PMID- 22759797
OWN - NLM
STAT- MEDLINE
DCOM- 20121204
LR  - 20171116
IS  - 1557-3117 (Electronic)
IS  - 1053-2498 (Linking)
VI  - 31
IP  - 8
DP  - 2012 Aug
TI  - Baseline NT-proBNP correlates with change in 6-minute walk distance in patients 
      with pulmonary arterial hypertension in the pivotal inhaled treprostinil study 
      TRIUMPH-1.
PG  - 811-6
LID - 10.1016/j.healun.2012.04.005 [doi]
AB  - BACKGROUND: N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a biomarker 
      of disease severity in pulmonary arterial hypertension (PAH). In this study we 
      aimed to determine whether baseline NT-proBNP levels correlate with improvement 
      in 6-minute walk distance (6MWD) in the pivotal randomized, placebo-controlled, 
      double-blind study of the addition of inhaled treprostinil to oral therapy for 
      PAH. METHODS: A post hoc analysis of data from the TRIUMPH-1 study was performed 
      in patients who had assessments of NT-proBNP levels and baseline and Week 12 
      6MWD. Least-squares mean analysis was used to compare patients in the highest 
      quartile of baseline NT-proBNP with those in lower quartiles with regard to 
      change from baseline in 6MWD, stratified by treatment. RESULTS: The NT-proBNP 
      within-treatment median changes from baseline to Week 12 were +44 and -72 pg/ml, 
      and the median changes in 6MWD from baseline to Week 12 were +5 and +40 m for the 
      placebo (n = 94) and inhaled treprostinil (n = 84) groups, respectively. Baseline 
      NT-proBNP levels demonstrated a strong interaction with treatment in predicting 
      change from baseline for 6MWD (p < 0.01), indicating that, in the upper quartile 
      (>/=1,513.5 pg/ml), patients on inhaled treprostinil had a better response (+64 vs 
      +32 m), whereas patients on placebo fared worse (-13 vs +20 m) when compared with 
      the lower 3 quartiles (<1,513.5 pg/ml). Furthermore, least-squares mean 
      difference in 6MWD between active and placebo groups was +67 and +16 m for the 
      upper and lower 3 quartiles of NT-proBNP, respectively. CONCLUSIONS: Greater 
      improvement in 6MWD in actively treated patients with high levels of NT-proBNP 
      enhances understanding of the robustness of clinical response to inhaled 
      treprostinil in more advanced disease.
CI  - Copyright (c) 2012 International Society for Heart and Lung Transplantation. 
      Published by Elsevier Inc. All rights reserved.
FAU - Frantz, Robert P
AU  - Frantz RP
AD  - Division of Cardiovascular Diseases, College of Medicine, Mayo Clinic, 200 First 
      Street SW, Rochester, MN 55905, USA. frantz.robert@mayo.edu
FAU - McDevitt, Susanne
AU  - McDevitt S
FAU - Walker, Susan
AU  - Walker S
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Heart Lung Transplant
JT  - The Journal of heart and lung transplantation : the official publication of the 
      International Society for Heart Transplantation
JID - 9102703
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Peptide Fragments)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - RUM6K67ESG (treprostinil)
SB  - IM
MH  - Administration, Inhalation
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antihypertensive Agents/administration & dosage/*therapeutic use
MH  - Biomarkers/blood
MH  - Double-Blind Method
MH  - Epoprostenol/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Hypertension, Pulmonary/blood/*drug therapy/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/*blood
MH  - Peptide Fragments/*blood
MH  - Predictive Value of Tests
MH  - Severity of Illness Index
MH  - Time Factors
MH  - Treatment Outcome
MH  - Walking/*physiology
MH  - Young Adult
EDAT- 2012/07/05 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/07/05 06:00
PHST- 2011/11/28 00:00 [received]
PHST- 2012/04/03 00:00 [revised]
PHST- 2012/04/29 00:00 [accepted]
PHST- 2012/07/05 06:00 [entrez]
PHST- 2012/07/05 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - S1053-2498(12)01076-5 [pii]
AID - 10.1016/j.healun.2012.04.005 [doi]
PST - ppublish
SO  - J Heart Lung Transplant. 2012 Aug;31(8):811-6. doi: 10.1016/j.healun.2012.04.005.